WE SEEK TO DELETE DISEASE BEFORE IT CAN EVADE OR BECOME INTRANSIGENT TO STANDARD MEDICAL TREATMENTS.
_Our pipeline comprises novel, targeted drug candidates aimed at early intervention—removing bacteria known to initiate infection and exacerbate dysbiosis, which often leads to a cascade of inflammation, tissue proliferation and/or damage, immune dysregulation, and in some
cancers, metastasis.
